Combination drug therapy demonstrates potential to treat AMD subtype
Data from patients with a subtype of AMD enrolled in Opthea’s Phase 2b clinical trial of OPT-302 in combination with ...
Data from patients with a subtype of AMD enrolled in Opthea’s Phase 2b clinical trial of OPT-302 in combination with ...
Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.
© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited
© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited